← All writing
Bench → Bedside · 8 min

Epigenetic editing is a question about control

Notes from a CRISPR/dCas9-TET1 project in porcine cumulus-oocyte complexes.

May 10, 2026

Genome editing often attracts attention because it sounds like a decisive act: cut, change, repair. Epigenetic editing feels different. It asks whether we can influence gene regulation without changing the underlying DNA sequence, and whether that influence can be precise enough to matter biologically. The ambition is still large, but the gesture is subtler.

In my PhD work, that question took shape around CRISPR/dCas9-TET1-mediated targeted DNA demethylation of MTNR1A in porcine cumulus-oocyte complexes. The scientific motivation was practical and developmental: could changing an epigenetic mark around a melatonin receptor pathway improve oocyte competence and later developmental capacity?

The project sat at an interesting boundary. On one side was molecular control: design a targeting strategy, deliver the system, measure expression, interpret methylation and downstream developmental outcomes. On the other side was reproductive biology, where cell state, culture conditions, timing, and sample quality can reshape what molecular control even means.

Precision is not just delivery

The difficulty of this kind of work is that precision is not only about molecular targeting. It is also about timing, cell state, culture conditions, assay design, and interpretation. A targeted system still enters a living context, and the context answers back.

This is one reason epigenetic editing is scientifically attractive and experimentally demanding. DNA methylation is not simply a label to remove. It is part of a regulatory environment. If we intervene, we have to ask whether the intervention is local enough, durable enough, biologically meaningful enough, and measured at the right time to justify our interpretation.

That has made me less interested in technological novelty by itself. A tool is exciting when it makes a better biological question possible. In reproductive biotechnology, the better question is rarely just whether an intervention changes a marker. It is whether that change improves the competence of a cell in a way that survives the next developmental step.

Competence is a hard endpoint

Oocyte competence is a demanding concept because it compresses many layers of biology into one word. It includes nuclear maturation, cytoplasmic maturation, mitochondrial function, gene regulation, cumulus-cell communication, fertilization potential, and the capacity to support early embryonic development. No single assay owns the definition.

That complexity is frustrating, but it is also useful. It prevents a project from becoming too narrow. If an intervention improves one molecular readout but fails to improve developmental outcomes, the system has told us something. If an intervention changes a developmental outcome but the mechanism remains unclear, the system has told us something else. Either way, competence forces the work to remain biological.

The CRISPR/dCas9-TET1 framework was therefore not only a technical strategy. It was a way to ask how much regulatory control can be gained inside a cell that is preparing for development. That question matters for embryo production, genome-edited animal models, fertility research, and the broader design of large-animal studies.

Why it matters beyond the oocyte

Oocyte competence may sound narrow, but it is connected to a wider translational world: embryo production, genome-edited animal models, fertility, genetic-resource preservation, and the ethical design of large-animal research. Epigenetic editing is one way of asking how much control we can responsibly gain over systems that remain deeply alive.

The word responsibly matters. If a technology increases our power to intervene, it should also increase our obligation to understand what the intervention means. In reproductive biotechnology, a successful protocol is not only one that produces an effect. It is one that produces an effect we can explain, reproduce, and place within a larger ethical frame.

That is the version of control I am interested in: not domination over biology, but disciplined participation in it. Epigenetic editing, at its best, teaches that control is always partial, always contextual, and always accountable to the living system in which it operates.